Brooks Automation, Inc. provides manufacturing automation solutions for the semiconductor industry, and life science sample-based services and solutions for the life sciences market worldwide. The company operates in three segments: Brooks Semiconductor Solutions Group, Brooks Life Sciences Services, and Brooks Life Sciences Products. The Brooks Semiconductor Solutions Group segment offers wafer automation and contamination controls solutions and services. Its products include atmospheric and vacuum robots, robotic modules, and tool automation systems that offer precision handling and clean wafer environments; and automated cleaning and inspection systems for wafer carriers, reticle pod cleaners, and stockers. It also offers repair and refurbishment, diagnostics, and installation services, as well as spare parts and productivity enhancement upgrade services. The Brooks Life Sciences Services segment provides gene sequencing and gene synthesis services, including next generation sequencing, sanger sequencing, gene synthesis, bioinformatics, and good laboratory practices regulatory services; on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery, and business continuity, as well as project management and consulting services; and sample intelligence software solutions and integration of customer technology. The Brooks Life Sciences Products segment offers automated cold storage systems; consumables, such as various formats of racks, tubes, caps, plates, and foils used for the storage and handling of samples in cold storage environments; and instruments used for labeling, bar coding, capping, de-capping, auditing, sealing, peeling, and piercing tubes and plates. The company serves semiconductor capital equipment and life sciences sample management markets in approximately 50 countries. Brooks Automation, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
IPO Year: 1995
Exchange: NASDAQ
Website: brooks.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2021 | $139.00 → $155.00 | Buy | Needham |
| 11/17/2021 | $146.00 → $132.00 | Overweight | Keybanc |
| 11/11/2021 | $100.00 → $120.00 | Neutral | Citigroup |
| 11/10/2021 | $121.00 → $139.00 | Buy | Needham |
| 9/7/2021 | $115.00 → $146.00 | Overweight | Keybanc |
| 8/6/2021 | $130.00 → $114.00 | Buy | Needham |
CHELMSFORD, Mass., Jan. 6, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has appointed Matthew McManus Chief Operating Officer effective January 17th. In this newly created role, Dr. McManus will oversee Life Sciences Products, Services, and all commercial operations of the business and will report directly to the CEO. "We are excited to have Matt join the Company as our COO," said Steve Schwartz, President and CEO of Azenta. "Matt brings decades of expertise in life sciences. His depth of knowledge and valuable perspective will enhance our leadership position in the markets we serve." Dr. McManus joins Azenta with over 25 years of experience in the life s
SC 13G - Brooks Automation, Inc. (0000933974) (Subject)
SC 13G/A - Brooks Automation, Inc. (0000933974) (Subject)
Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or the "Company") announced today that it has completed its previously announced corporate name change from "Brooks Automation, Inc." to "Azenta, Inc." In conjunction with the corporate name change, the Company will begin trading on the Nasdaq Global Select Market under the new ticker symbol, AZTA, effective at the open of market trading on December 1, 2021. This change follows the launch of the Company's life sciences brand, Azenta Life Sciences and the Investor Day held on November 16, 2021. The Company anticipates completion of the sale of the semiconductor automation business in the first half of calendar year 2022, at which time the Company will bec
Needham reiterated coverage of Brooks Automation with a rating of Buy and set a new price target of $155.00 from $139.00 previously
Keybanc reiterated coverage of Brooks Automation with a rating of Overweight and set a new price target of $132.00 from $146.00 previously
Citigroup reiterated coverage of Brooks Automation with a rating of Neutral and set a new price target of $120.00 from $100.00 previously
Needham reiterated coverage of Brooks Automation with a rating of Buy and set a new price target of $139.00 from $121.00 previously
Keybanc reiterated coverage of Brooks Automation with a rating of Overweight and set a new price target of $146.00 from $115.00 previously
Needham reiterated coverage of Brooks Automation with a rating of Buy and set a new price target of $114.00 from $130.00 previously
B. Riley Securities reiterated coverage of Brooks Automation with a rating of Buy and set a new price target of $130.00 from $125.00 previously
Credit Suisse reiterated coverage of Brooks Automation with a rating of Neutral and set a new price target of $85.00 from $70.00 previously
Needham reiterated coverage of Brooks Automation with a rating of Buy and set a new price target of $130.00 from $110.00 previously
Keybanc reiterated coverage of Brooks Automation with a rating of Overweight and set a new price target of $115.00 from $111.00 previously
4 - Brooks Automation, Inc. (0000933974) (Issuer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
4/A - Brooks Automation, Inc. (0000933974) (Issuer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
8-K - Azenta, Inc. (0000933974) (Filer)
10-K - Brooks Automation, Inc. (0000933974) (Filer)
8-K - Brooks Automation, Inc. (0000933974) (Filer)
8-K - Brooks Automation, Inc. (0000933974) (Filer)
8-K - Brooks Automation, Inc. (0000933974) (Filer)
8-K - Brooks Automation, Inc. (0000933974) (Filer)
8-K - Brooks Automation, Inc. (0000933974) (Filer)
10-Q - Brooks Automation, Inc. (0000933974) (Filer)
SD - Brooks Automation, Inc. (0000933974) (Filer)
10-Q - Brooks Automation, Inc. (0000933974) (Filer)
CHELMSFORD, Mass., Nov. 7, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2022 earnings which ended on September 30, 2022 on Monday, November 14, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Monday, November 14, 2022 at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-936-4761 for domestic callers and +1-212-231-2922 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:3
CHELMSFORD, Mass., Aug. 9, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2022. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2022 2022 2021 Prior Qtr. Prior Yr. Revenue from Continuing Operations $ 133 $ 146 $ 129 (9) % 3 % Life Sciences Products $ 47 $ 54 $ 49 (12) % (3) % Life Sciences Services $ 85 $ 92 $ 80 (7) % 6 % Diluted EPS Continuing Operations $ (0.09) $ (0.02) $ (0.02) nm nm Diluted EPS Total $ (0.13) $ 28.28 $ 0.53 nm nm Non-GAAP Diluted EPS Continuing Operations $ 0.12 $ 0.12 $ 0.10 0 % 14 % Adjusted EBITDA Continuing Operations $ 14 $ 19 $ 19 (29) % (26) % M
Enhances Azenta's Leadership Position in Cold Chain Solutions and End-to-End Sample Management CHELMSFORD, Mass., Aug. 8, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered into a definitive agreement to acquire B Medical Systems S.á r.l and its subsidiaries ("B Medical"), a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments across the globe. The cash purchase price to be paid at closing will be approximately €410 million. Additional cash consideration, up to €50 million, may be paid upon achievement of certain future performance milestones. The transaction is expected to close in O
CHELMSFORD, Mass., July 13, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported preliminary results for its third fiscal quarter ended June 30, 2022. The Company expects revenue of approximately $133 million, an increase of 3% compared to the third quarter of fiscal 2021. Year-over-year organic growth is expected to be 6%, after adjusting for approximately 3 percentage points of currency impact. GAAP diluted EPS from continuing operations is expected to be in the range of ($0.13) to ($0.08), driven lower than expected primarily due to income taxes. Non-GAAP diluted EPS is expected to be in the range of $0.08 to $0.12. Revenue for the Services segment is expected to be approximatel
Robust customer demand bolstered by operational execution drives strong second quarter results CHELMSFORD, Mass., May 9, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported preliminary financial results for the second quarter ended March 31, 2022. Summary of Preliminary Results On February 1, 2022, the Company completed the sale of its Semiconductor Automation business. The related gain on the sale and the results of the Semiconductor Automation business are treated as discontinued operations and reflected in total diluted EPS. Due to the complexities of the financial carve-out of the business from the Company's financial results, the Company expects it will require additional
CHELMSFORD, Mass., April 28, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has rescheduled the release of its earnings for the second fiscal quarter of 2022 which ended on March 31, 2022 from Tuesday, May 3, 2022 to Monday, May 9, 2022 after the market closes. The change is due to a delay in completing the quarter-end closing process related to the sale of the Semiconductor Automation business, which closed on February 1, 2022. Azenta currently expects second quarter revenue and non-GAAP EPS to be within the previously issued guidance range. The Company will host a conference call and live webcast to discuss its financial results on the same day, Monday, May 9, 2022
CHELMSFORD, Mass., April 14, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal 2022 second quarter earnings which ended on March 31, 2022 on Tuesday, May 3, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, May 3, 2022 at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-926-6194 for domestic callers and +1-212-231-2922 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 4, 2022. Ab
CHELMSFORD, Mass., Feb. 8, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fiscal quarter ended December 31, 2021. Summary of Results Results of continuing operations reflect the Life Sciences business. Due to the agreement reached in the fourth fiscal quarter of 2021 to divest the semiconductor automation business, the results of the semiconductor automation business are treated as discontinued operations and reflected in total diluted EPS. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2021 2021 2020 Prior Qtr. Prior Yr. Revenue from Continuing Operations $ 140 $ 137 $ 118 2 % 18 % Life Sci
CHELMSFORD, Mass, Jan. 24, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal 2022 first quarter earnings which ended on December 31, 2021 on Tuesday, February 8, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, February 8, 2022 at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-584-1012 for domestic callers and +1-212-231-2907 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m.
CHELMSFORD, Mass., Nov. 10, 2021 /PRNewswire/ -- Brooks Automation, Inc. (NASDAQ:BRKS) today reported financial results for the fiscal quarter ended September 30, 2021. Summary of GAAP ResultsResults of continuing operations reflect the Life Sciences business. Due to the announced divestiture in the fourth fiscal quarter of 2021, results of the Semiconductor Automation business are treated as discontinued operations and reflected in total diluted EPS. Quarter Ended Year Ended Dollars in millions, except per share data September 30, September 30, September 30, September 30, 2021 2020 Change 2021 2020 Change Revenue - Continuing Operations $ 137 $ 108 27 % $ 514 $ 389 32 % Diluted EPS - C
CHELMSFORD, Mass., Nov. 7, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2022 earnings which ended on September 30, 2022 on Monday, November 14, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Monday, November 14, 2022 at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-936-4761 for domestic callers and +1-212-231-2922 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:3
CHELMSFORD, Mass., Oct. 3, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has closed its previously announced acquisition of B Medical Systems S.á r.l and its subsidiaries ("B Medical"), a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to more than 150 countries worldwide. This acquisition complements Azenta's cold chain capabilities, adding differentiated solutions for reliable and traceable transport of temperature-sensitive specimens. B Medical, headquartered in Hosingen, Luxembourg, is one of the leading vaccine cold chain providers serving primarily fast-growing emerging markets, w
CHELMSFORD, Mass., Sept. 6, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the Baird 2022 Global Healthcare Conference in New York City, on Wednesday, September 14, 2022, which includes a presentation beginning at 9:40 am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain
CHELMSFORD, Mass., Aug. 30, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York City, on Tuesday, September 13, 2022, which includes a presentation beginning at 4:40 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliabl
CHELMSFORD, Mass., Aug. 11, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16, 2022. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. As of December
CHELMSFORD, Mass., Aug. 9, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2022. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2022 2022 2021 Prior Qtr. Prior Yr. Revenue from Continuing Operations $ 133 $ 146 $ 129 (9) % 3 % Life Sciences Products $ 47 $ 54 $ 49 (12) % (3) % Life Sciences Services $ 85 $ 92 $ 80 (7) % 6 % Diluted EPS Continuing Operations $ (0.09) $ (0.02) $ (0.02) nm nm Diluted EPS Total $ (0.13) $ 28.28 $ 0.53 nm nm Non-GAAP Diluted EPS Continuing Operations $ 0.12 $ 0.12 $ 0.10 0 % 14 % Adjusted EBITDA Continuing Operations $ 14 $ 19 $ 19 (29) % (26) % M
Enhances Azenta's Leadership Position in Cold Chain Solutions and End-to-End Sample Management CHELMSFORD, Mass., Aug. 8, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered into a definitive agreement to acquire B Medical Systems S.á r.l and its subsidiaries ("B Medical"), a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments across the globe. The cash purchase price to be paid at closing will be approximately €410 million. Additional cash consideration, up to €50 million, may be paid upon achievement of certain future performance milestones. The transaction is expected to close in O
CHELMSFORD, Mass., Aug. 5, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, CA, on Thursday, August 11, 2022, which includes a presentation beginning at 4:00 pm PT. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-ch
CHELMSFORD, Mass., July 27, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the opening of its new China headquarters in Suzhou, which serves as the hub for Azenta operations in the Asia Pacific region. The project is the largest capital investment to date for Azenta and consists of over 200,000 square feet of laboratory and office space. The new facility consolidates multiple leased spaces into a single owned facility and significantly expands the capacity of Azenta labs in China. "This strategic investment is enabling customers to advance therapeutics develop
CHELMSFORD, Mass., July 13, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported preliminary results for its third fiscal quarter ended June 30, 2022. The Company expects revenue of approximately $133 million, an increase of 3% compared to the third quarter of fiscal 2021. Year-over-year organic growth is expected to be 6%, after adjusting for approximately 3 percentage points of currency impact. GAAP diluted EPS from continuing operations is expected to be in the range of ($0.13) to ($0.08), driven lower than expected primarily due to income taxes. Non-GAAP diluted EPS is expected to be in the range of $0.08 to $0.12. Revenue for the Services segment is expected to be approximatel